Life Extension Spring Clearance Sale

Gastroesophageal Reflux Disease (GERD) References

Disease Prevention and Treatment, 5th edition

The references on this page correspond with the print version of Disease Prevention and Treatment, 5th edition. Since we continuously update the protocols online in response to new scientific developments, readers are encouraged to review the latest versions of the protocols.

  1. Patti MG and Katz J. Gastroesophageal Reflux Disease. Available at: http://emedicine.medscape.com/article/176595-overview#a0156 Accessed 4/5/2012
  2. Longstreth G. Gastroesophageal reflux disease. Revised 8/11/2011 Available at: http://www.nlm.nih.gov/medlineplus/ency/article/000265.htm Accessed 4/6/2012
  3. Richter J and Friedenberg F. Gastroesophageal Reflux Disease. In: Feldman: Sleisenger and Fordtran's Gastrointestinal and Liver Disease. 9th ed. Philadelphia, PA: Saunders Elsevier; 2010. MD Consult website. Available at http://www.mdconsult.com/books/page.do?eid=4-u1.0-B978-1-4160-6189-2..00043-3&isbn=978-1-4160-6189-2&uniqId=328043000-6#4-u1.0-B978-1-4160-6189-2..00043-3--s0010. Accessed April 6, 2012.
  4. Locke GR, et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology. 1997 May;112(5):1448-56.
  5. Katz MH. Failing the Acid Test: Benefits of Proton Pump Inhibitors May Not Justify the Risks for Many Users. Arch Intern Med. 2010;170(9):747-748.
  6. Corley DA, Kubo A, Zhao W, et al. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology. 2010 Jul;139(1):93-101. Epub 2010 Mar 27.
  7. Khalili H, Huang E, Jacobson B, et al. Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study BMJ. 2012; 344: e372. Published online 2012 January 31.
  8. Sheen E and Triadafilopoulos G. Adverse effects of long-term proton pump inhibitor therapy. Dig Dis Sci. 2011 Apr;56(4):931-50.
  9. Roulet L, Vernaz N, Giostra E, et al. [Adverse effects of proton pump inhibitors: Should we worry about long-term exposure?] Rev Med Interne. 2012 Jan 26. [Epub ahead of print]
  10. Fass R. Proton pump inhibitor failure--what are the therapeutic options? Am J Gastroenterol. 2009; 104 Suppl 2:S33-8
  11. Kuo B, Urma D. GI Motility online (2006) Esophagus - anatomy and development accessed 4/2/2012. Available at: http://www.nature.com/gimo/contents/pt1/full/gimo6.html
  12. Stefanidis D, Hope WW, Kohn GP, et al. Guidelines for surgical treatment of gastroesophageal reflux disease. Surg Endosc. 2010;24(11):2647–2669.
  13. Bredenoord AJ. Mechanisms of reflux perception in gastroesophageal reflux disease: a review. Am J Gastroenterol. 2012;107(1):8–15.
  14. McQuaid KR, Laine L, Fennerty MB, Souza R, Spechler SJ. Systematic review: the role of bile acids in the pathogenesis of gastro-oesophageal reflux disease and related neoplasia. Aliment. Pharmacol. Ther. 2011;34(2):146–165.
  15. Martinez SD, Malagon IB, Garewal HS, Cui H, Fass R. Non-erosive reflux disease (NERD)--acid reflux and symptom patterns. Aliment. Pharmacol. Ther. 2003;17(4):537–545.
  16. Shi G, et al. Reflux related symptoms in patients with normal oesophageal exposure to acid. Gut. 1995 Oct;37(4):457-64.
  17. Nasr AO, Dillon MF, Conlon S, et al. Acid suppression increases rates of Barrett's esophagus and esophageal injury in the presence of duodenal reflux. Surgery. 2012;151(3):382–390.
  18. Tutuian R. Adverse effects of drugs on the esophagus. Best Pract Res Clin Gastroenterol. 2010 Apr;24(2):91-7.
  19. Arora AS, Yamazaki K. Eosinophilic esophagitis: asthma of the esophagus? Clin Gastroenterol Hepatol. 2004;2(7):523–530.
  20. Gonsalves N, Kahrilas PJ. Eosinophilic oesophagitis in adults. Neurogastroenterol. Motil. 2009;21(10):1017–1026.
  21. Foroutan M, Norouzi A, Molaei M, et al. Eosinophilic esophagitis in patients with refractory gastroesophageal reflux disease. Dig. Dis. Sci. 2010;55(1):28–31.
  22. Spergel JM, et al. Treatment of eosinophilic esophagitis with specific food elimination diet directed by a combination of skin prick and patch tests. Ann Allergy Asthma Immunol. 2005 Oct;95(4):336-43.
  23. Price SF, Smithson KW, Castell DO. Food sensitivity in reflux esophagitis. Gastroenterology. 1978 Aug;75(2):240-3.
  24. Semeniuk J, Kaczmarski M, Uscinowicz M, et al. Histological evaluation of esophageal mucosa in children with acid gastroesophageal reflux. Folia Histochem Cytobiol. 2009;47(2):297-306.Shaheen NJ, Hansen RA, Morgan DR, et al. The burden of gastrointestinal and liver diseases, 2006. Am J Gastroenterol. 2006;101(9):2128–2138.
  25. Gonsalves N, Yang GY, Doerfler B, et al. Elimination Diet Effectively Treats Eosinophilic Esophagitis in Adults; Food Reintroduction Identifies Causative Factors. Gastroenterology. 2012 Mar 2. [Epub ahead of print].
  26. O’Connor HJ. Review article: Helicobacter pylori and gastro-oesophageal reflux disease-clinical implications and management. Aliment Pharmacol Ther. 1999 Feb;13(2):117-27.
  27. Ferri F. Gastroesophageal Reflux Disease. Ferri's Clinical Advisor 2012, 1st ed. Philadelphia, Pa: Elsevier Mosby; 2012. MD Consult Web site. Available at http://www.mdconsult.com/books/page.do?eid=4-u1.0-B978-0-323-05611-3..00016-1--sc0030&isbn=978-0-323-05611-3&sid=1288234964&uniqId=326497910-3#4-u1.0-B978-0-323-05611-3..00016-1--s0435. Accessed March 28, 2012.
  28. Haruma K, Manabe N, Kamada T, et al. Helicobacter pylori infection and GERD]. Nihon Rinsho. 2007 May;65(5):841-5.
  29. Saad AM, Choudhary A, Bechtold ML. Effect of Helicobacter pylori treatment on gastroesophageal reflux disease (GERD): meta-analysis of randomized controlled trials. Scand J Gastroenterol. 2012 Feb;47(2):129-35.
  30. Yaghoobi M, Farrokhyar F, Yuan Y, et al. Is there an increased risk of GERD after Helicobacter pylori eradication?: a meta-analysis. Am J Gastroenterol. 2010 May;105(5):1007-13; quiz 1006, 1014.
  31. Wright J, Lenard L. Why Stomach Acid Is Good for You: Natural Relief from Heartburn, Indigestion, Reflux and GERD. Lanham, Maryland: M. Evans. 2001. Print.
  32. Kern RA, Rose E, Austin JH. THE EFFECT OF ORALLY ADMINISTERED HYDROCHLORIC ACID UPON THE GASTRIC CONTENTS IN NORMAL INDIVIDUALS AND IN PATIENTS WITH ACHLORHYDRIA. J CLIN INVEST. 1926 AUG;2(6):545-77.
  33. Kamal A, Vaezi MF. Diagnosis and initial management of gastroesophageal complications. Best Pract Res Clin Gastroenterol. 2010;24(6):799–820.
  34. Amarasiri LD, Pathmeswaran A, de Silva HJ, Ranasinha CD. Prevalence of gastro-oesophageal reflux disease symptoms and reflux-associated respiratory symptoms in asthma. BMC Pulm Med. 2010 Sep 15;10:49.
  35. Bresci G, Sacco R. Pulmonary or otolaryngologic extraesophageal manifestations in patients with gastroesophageal reflux disease. World J Gastrointest Endosc. 2010 Feb 16;2(2):47-9.
  36. Lee JS, Collard HR, Raghu G, et al. Does chronic microaspiration cause idiopathic pulmonary fibrosis? Am J Med. 2010 Apr;123(4):304-11.
  37. Fahim A, Crooks M, Hart SP. Gastroesophageal reflux and idiopathic pulmonary fibrosis: a review. Pulm Med. 2011;2011:634613. Epub 2010 Dec 9.
  38. Rosemurgy AS, Donn N, Paul H, Luberice K, Ross SB. Gastroesophageal reflux disease. Surg. Clin. North Am. 2011;91(5):1015–1029.
  39. Horvath KD, Swanstrom LL, Jobe BA. The short esophagus: pathophysiology, incidence, presentation, and treatment in the era of laparoscopic antireflux surgery. Ann Surg. 2000 Nov;232(5):630-40.
  40. Hoang CD, Koh PS, Maddaus MA. Short esophagus and esophageal stricture. Surg. Clin. North Am. 2005;85(3):433–451.
  41. Chen H, Fang Y, Tevebaugh W, Orlando RC, Shaheen NJ, Chen X. Molecular mechanisms of Barrett's esophagus. Dig. Dis. Sci. 2011;56(12):3405–3420.
  42. Gerson L, Shetler K, Triadafilopoulos G. Prevalence of Barrett's esophagus in asymptomatic individuals. Gastroenterology. 2002;123(2):461–467.
  43. Toruner M, Soykan I, Ensari A, Kuzu I, Yurdaydin C, Ozden A. Barrett's esophagus: prevalence and its relationship with dyspeptic symptoms. Journal of Gastroenterology and Hepatology. 2004;19(5):535–540.
  44. Lekakos L, Karidis NP, Dimitroulis D, et al. Barrett's esophagus with high-grade dysplasia: focus on current treatment options. World J Gastroenterol. 2011 Oct 7;17(37):4174-83.
  45. Siersema PD. Pathogenesis, diagnosis and therapeutic possibilities of esophageal cancer. Curr Opin Gastroenterol. 2007;23(4):456–461.
  46. de Jonge PJF, van Blankenstein M, Looman CWN, Casparie MK, Meijer GA, Kuipers EJ. Risk of malignant progression in patients with Barrett's oesophagus: a Dutch nationwide cohort study. Gut. 2010;59(8):1030–1036.
  47. Wani S, Falk G, Hall M, et al. Patients With Nondysplastic Barrett's Esophagus Have Low Risks for Developing Dysplasia or Esophageal Adenocarcinoma. Clinical Gastroenterology and Hepatology. 2011;9(3):220–227.
  48. DeVault KR, Castell DO. American College of Gastroenterology. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol. 2005;100(1):190–200.
  49. Jones R, Junghard O, Dent J, et al. Development of the GerdQ, a tool for the diagnosis and management of gastro-oesophageal reflux disease in primary care. Aliment. Pharmacol. Ther. 2009;30(10):1030–1038.
  50. Ponce J, Garrigues V, Agréus L, et al. Structured management strategy versus usual care for gastroesophageal reflux disease: rationale for pooled analysis of five European cluster-randomized trials. Therap Adv Gastroenterol. 2011;4(1):11-26.
  51. Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R. Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. In The American journal of gastroenterology, p. 1900–20; quiz 1943.
  52. Roman S, Mion F, Benamouzig R, et al. Wireless pH capsule--yield in clinical practice. Endoscopy. 2012 Mar;44(3):270-6.
  53. Domingues GR, Moraes-Filho JP, Domingues AG. Impact of prolonged 48-h wireless capsule esophageal pH monitoring on diagnosis of gastroesophageal reflux disease and evaluation of the relationship between symptoms and reflux episodes. Arq Gastroenterol. 2011 Jan-Mar;48(1):24-9.
  54. Johnson L, DeMeester T. Twenty-four-hour pH monitoring of the distal esophagus. A quantitative measure of gastroesophageal reflux. Am J Gastroenterol. 1974;62:325–332.
  55. Lazarescu A, Sifrim D. Ambulatory monitoring of GERD: current technology. Gastroenterol. Clin. North Am. 2008;37(4):793–805, viii.
  56. Holloway R. Esophageal manometry. GI Motility online. 2006.
  57. Kim JW, Kim HS, Lee DK, et al. [Therapeutic effect of low-dose omeprazole vs. standard-dose ranitidine in mild to moderate reflux esophagitis]. Korean J Gastroenterol. 2004 Mar;43(3):153-9.
  58. Vanderhoff BT and Tahboub RM. Proton pump inhibitors: an update. Am Fam Physician. 2002 Jul 15;66(2):273-80.
  59. Bruley des Varannes S, Coron E, Galmiche JP. Short and long-term PPI treatment for GERD. Do we need more-potent anti-secretory drugs? Best Pract Res Clin Gastroenterol. 2010 Dec;24(6):905-21.
  60. Al-Quaiz JM. Iron deficiency anemia. A study of risk factors. Saudi Med J. 2001;22(6):490–496.
  61. Ruscin JM, Page RL, Valuck RJ. Vitamin B(12) deficiency associated with histamine(2)-receptor antagonists and a proton-pump inhibitor. Ann Pharmacother. 2002;36(5):812–816.
  62. Dali-Youcef N, Andrès E. An update on cobalamin deficiency in adults. QJM. 2009;102(1):17–28.
  63. O'Connell MB, Madden DM, Murray AM, Heaney RP, Kerzner LJ. Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am. J. Med. 2005;118(7):778–781.
  64. Sarzynski E, Puttarajappa C, Xie Y, Grover M, Laird-Fick H. Association between proton pump inhibitor use and anemia: a retrospective cohort study. Dig. Dis. Sci. 2011;56(8):2349–2353.
  65. Yang YX, Lewis JD, Epstein S, Metz, D. C. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296(24):2947–2953.
  66. Pali-Scholl I, Jensen-Jarolim E. Anti-acid medication as a risk factor for food allergy. Allergy. 2011 Apr;66(4):469-77.
  67. Pomiecinski F, Yang AC, Navarro-Rodrigues T, et al. Sensitization to foods in gastroesophageal reflux disease and its relation to eosinophils in the esophagus: is it of clinical importance? Ann Allergy Asthma Immunol. 2010 Nov;105(5):359-63.
  68. Deshpande A, Pant C, Pasupuleti V, et al. Association Between Proton Pump Inhibitor Therapy and Clostridium difficile Infection in a Meta-Analysis. Clin. Gastroenterol. Hepatol. 2012;10(3):225–233.
  69. Bavishi C, Dupont HL. Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection. Aliment. Pharmacol. Ther. 2011;34(11-12):1269–1281.
  70. Song MJ, Park DI, Park JH, et al. The effect of probiotics and mucoprotective agents on PPI-based triple therapy for eradication of Helicobacter pylori. Helicobacter. 2010;15(3):206–213.
  71. Ratuapli SK, Ellington TG, O’Neill MT, et al. Proton Pump Inhibitor Therapy Use Does Not Predispose to Small Intestinal Bacterial Overgrowth. Am J Gastroenterol. 2012 Feb 14. doi: 10.1038/ajg.2012.4.
  72. Sheen E, Triadafilopoulos G. Adverse effects of long-term proton pump inhibitor therapy. Dig Dis Sci. 2011 Apr;56(4):931-50.
  73. Food and Drug Administration (FDA). Possible Increased Risk of Bone Fractures With Certain Antacid Drugs. Available at: http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm213240.htm Accessed 4/12/2012.
  74. Tan G, Yang Z, Wang, Z. Meta-analysis of laparoscopic total (Nissen) versus posterior (Toupet) fundoplication for gastro-oesophageal reflux disease based on randomized clinical trials. ANZ J Surg. 2011;81(4):246–252.
  75. Mariette C, Pessaux P. Ambulatory laparoscopic fundoplication for gastroesophageal reflux disease: a systematic review. Surg Endosc. 2011;25(9):2859–2864.
  76. Dibley LB, Norton C, Jones R. Non-pharmacological intervention for gastro-oesophageal reflux disease in primary care. Br J Gen Pract. 2010;60(581):e459–65.
  77. Bhatia SJ, Reddy DN, Ghoshal UC, et al. Epidemiology and symptom profile of gastroesophageal reflux in the Indian population: report of the Indian Society of Gastroenterology Task Force. Indian J Gastroenterol. 2011 May;30(3):118-27.
  78. Bujanda L, Cosme A, Muro N, et al. [Influence of lifestyle in patients with gastroesophageal reflux disease]. Med Clin (Barc). 2007 Apr 14;128(14):550-4.
  79. Song JH, Chung SJ, Lee JH, et al. Relationship between gastroesophageal reflux symptoms and dietary factors in Korea. J Neurogastroenterol Motil. 2011 Jan;17(1):54-60. Epub 2011 Jan 26.
  80. Hamoui N, Lord RV, Hagen JA, Theisen J, Demeester TR, Crookes PF. Response of the lower esophageal sphincter to gastric distention by carbonated beverages. J. Gastrointest. Surg. 2006;10(6):870–877.
  81. Grande L, Monforte R, Ros E, et al. High amplitude contractions in the middle third of the oesophagus: a manometric marker of chronic alcoholism? Gut. 1996;38(5):655–662.
  82. Kaltenbach T, Crockett S, Gerson LB. Are lifestyle measures effective in patients with gastroesophageal reflux disease? An evidence-based approach. Arch Intern Med. 2006;166(9):965–971.
  83. Nilsson M, Johnsen R, Ye W, Hveem K, Lagergren J. Lifestyle related risk factors in the aetiology of gastro-oesophageal reflux. Gut. 2004;53(12):1730–1735.
  84. Festi D, Scaioli E, Baldi F, et al. Body weight, lifestyle, dietary habits and gastroesophageal reflux disease. World J Gastroenterol. 2009;15(14):1690–1701.
  85. Hampel H, Abraham NS, El-Serag HB. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med. 2005;143(3):199–211.
  86. De Ceglie A, Fisher DA, Filiberti R. Barrett's esophagus, esophageal and esophagogastric junction adenocarcinomas: the role of diet. Clin Res Hepatol Gastroenterol. 2011 Jan;35(1):7-16.
  87. Colombo P, Mangano M, Bianchi PA, Penagini R. Effect of calories and fat on postprandial gastro-oesophageal reflux. Scand. J. Gastroenterol. 2002;37(1):3–5.
  88. Fox M, Barr C, Nolan S, Lomer M, Anggiansah A, Wong T. The effects of dietary fat and calorie density on esophageal acid exposure and reflux symptoms. Clin. Gastroenterol. Hepatol. 2007;5(4):439–444.
  89. Iwakiri K, Kobayashi M, Kotoyori M, Yamada H, Sugiura T, Nakagawa Y. Relationship between postprandial esophageal acid exposure and meal volume and fat content. Dig. Dis. Sci. 1996;41(5):926–930.
  90. Penagini RR, Mangano MM, Bianchi PAP. Effect of increasing the fat content but not the energy load of a meal on gastro-oesophageal reflux and lower oesophageal sphincter motor function. Gut. 1998;42(3):330–333.
  91. Austin GL, Thiny MT, Westman EC, Yancy WS, Shaheen NJ. A very low-carbohydrate diet improves gastroesophageal reflux and its symptoms. Dig. Dis. Sci. 2006;51(8):1307–1312.
  92. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol. 1999;94(6):1434–1442.
  93. Gerson LB, Fass R. A systematic review of the definitions, prevalence, and response to treatment of nocturnal gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2009 Apr;7(4):372-8; quiz 367.
  94. Orr WC, Harnish MJ. Sleep-related gastro-oesophageal reflux: provocation with a late evening meal and treatment with acid suppression. Aliment. Pharmacol. Ther. 1998;12(10):1033–1038.
  95. Lanzon-Miller S, Pounder RE, McIsaac RL, Wood JR. The timing of the evening meal affects the pattern of 24-hour intragastric acidity. Aliment. Pharmacol. Ther. 1990;4(5):547–553.
  96. Kotzan J, Wade W, Yu HH. Assessing NSAID prescription use as a predisposing factor for gastroesophageal reflux disease in a Medicaid population. Pharm Res. 2001 Sep;18(9):1367-72.
  97. Hampson FC, Jolliffe IG, Bakhtyari A, et al. Alginate-antacid combinations: raft formation and gastric retention studies. Drug Dev Ind Pharm. 2010;36(5):614–623.
  98. Mandel KG, Daggy BP, Brodie DA, Jacoby HI. Review article: alginate-raft formulations in the treatment of heartburn and acid reflux. Aliment. Pharmacol. Ther. 2000;14(6):669–690.
  99. Pouchain D, Bigard MA, Liard F, Childs M, Decaudin A, McVey D. Gaviscon(R) vs. Omeprazole in symptomatic treatment of moderate gastroesophageal reflux. A direct comparative randomised trial. BMC Gastroenterol. 2012;12(1):18.
  100. Werbach MR. Melatonin for the treatment of gastroesophageal reflux disease. Altern Ther Health Med. 2008;14(4):54–58.
  101. Konturek SJ, Zayachkivska O, Havryluk XO, et al. Protective influence of melatonin against acute esophageal lesions involves prostaglandins, nitric oxide and sensory nerves. J. Physiol. Pharmacol. 2007;58(2):361–377.
  102. Pereira Rde S. Regression of gastroesophageal reflux disease symptoms using dietary supplementation with melatonin, vitamins and aminoacids: comparison with omeprazole. J. Pineal Res. 2006;41(3):195–200.
  103. Kandil TS, Mousa AA, El-Gendy AA, Abbas AM. The potential therapeutic effect of melatonin in Gastro-Esophageal Reflux Disease. BMC Gastroenterol. 2010;10:7.
  104. Willette RC, Barrow L, Doster R, Wilkins J, Wilkins JS, Heggers JP. Purified d-limonene: an effective agent for the relief of occasional symptoms of heartburn. Proprietary study. WRC Laboratories, Inc. Galveston, TX.
  105. Wittschier N, Faller G, Hensel A. Aqueous extracts and polysaccharides from liquorice roots (Glycyrrhiza glabra L.) inhibit adhesion of Helicobacter pylori to human gastric mucosa. J Ethnopharmacol. 2009 Sep 7;125(2):218-23. Epub 2009 Jul 14.
  106. Martin H. DGL Licorice and Acid Reflux. 5/4/2011. Accessed 3/20/2012. Available at: http://www.livestrong.com/article/110565-dgl-licorice-acid-reflux/
  107. Chen H, Ward MH, Graubard BI, et al. Dietary patterns and adenocarcinoma of the esophagus and distal stomach. Am J Clin Nutr. 2002;75(1):137–144.
  108. Navarro Silvera SA, Mayne ST, Risch H, et al. Food group intake and risk of subtypes of esophageal and gastric cancer. Int J Cancer. 2008;123(4):852–860.
  109. Navarro Silvera SA, Mayne ST, Risch HA, et al. Principal component analysis of dietary and lifestyle patterns in relation to risk of subtypes of esophageal and gastric cancer. Ann Epidemiol. 2011;21(7):543–550.
  110. Gonzalez CA, Pera G, Agudo A, et al. Fruit and vegetable intake and the risk of stomach and oesophagus adenocarcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST). Int J Cancer. 2006;118(10):2559–2566.
  111. Steevens J, Schouten LJ, Goldbohm RA, van den Brandt PA. Vegetables and fruits consumption and risk of esophageal and gastric cancer subtypes in the Netherlands Cohort Study. Int J Cancer. 2011;129(11):2681–2693.
  112. Chen T, Yan F, Qian J, et al. Randomized phase II trial of lyophilized strawberries in patients with dysplastic precancerous lesions of the esophagus. Cancer Prev Res (Phila). 2012 Jan;5(1):41-50.
  113. Mayne ST, Risch HA, Dubrow R, et al. Nutrient intake and risk of subtypes of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev. 2001;10(10):1055–1062.
  114. Terry P, Lagergren J, Ye W, et al. Inverse association between intake of cereal fiber and risk of gastric cardia cancer. Gastroenterology. 2001;120(2):387-91.
  115. Bollschweiler E, Wolfgarten E, Nowroth T, Rosendahl U, Mönig SP, Hölscher AH. Vitamin intake and risk of subtypes of esophageal cancer in Germany. J. Cancer Res. Clin. Oncol. 2002;128(10):575–580.
  116. Kubo A, Corley DA. Meta-analysis of antioxidant intake and the risk of esophageal and gastric cardia adenocarcinoma. Am J Gastroenterol. 2007;102(10):2323–30; quiz 2331.
  117. Carman S, Kamangar F, Freedman ND, et al. Vitamin E intake and risk of esophageal and gastric cancers in the NIH-AARP Diet and Health Study. Int J Cancer. 2009;125(1):165–170.
  118. Ibiebele TI, Hughes MC, Pandeya N, et al. High intake of folate from food sources is associated with reduced risk of esophageal cancer in an Australian population. Journal of Nutrition. 2011;141(2):274–283.
  119. Dong LM, Kristal AR, Peters U, et al. Dietary supplement use and risk of neoplastic progression in esophageal adenocarcinoma: a prospective study. Nutr Cancer. 2008;60(1):39–48.
  120. Whitley AC, Sweet DH, Walle T. The dietary polyphenol ellagic acid is a potent inhibitor of hOAT1. Drug Metab Dispos. 2005 Aug;33(8):1097-100.
  121. Beserra AM, Calegari PI, Souza Mdo C, et al. Gastroprotective and ulcer-healing mechanisms of ellagic acid in experimental rats. J Agric Food Chem. 2011 Jul 13;59(13):6957-65. Epub 2011 Jun 16.
  122. Qazi A, Pal J, Maitah M, et al. Anticancer activity of a broccoli derivative, sulforaphane, in barrett adenocarcinoma: potential use in chemoprevention and as adjuvant in chemotherapy. Transl Oncol. 2010;3(6):389–399.
  123. Hao J, Zhang B, Liu B, et al. Effect of alpha-tocopherol, N-acetylcysteine and omeprazole on esophageal adenocarcinoma formation in a rat surgical model. Int J Cancer. 2009;124(6):1270–1275.
  124. Pierini R, Kroon PA, Guyot S, Ivory K, Johnson IT, Belshaw NJ. Procyanidin effects on oesophageal adenocarcinoma cells strongly depend on flavan-3-ol degree of polymerization. Mol. Nutr. Food Res. 2008;52(12):1399–1407.
  125. Kresty LA, Howell AB, Baird M. Cranberry proanthocyanidins induce apoptosis and inhibit acid-induced proliferation of human esophageal adenocarcinoma cells. J Agric Food Chem. 2008;56(3):676–680.